Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
- Conditions
- Ulcerative ColitisCrohn's Disease
- Interventions
- Registration Number
- NCT03884439
- Lead Sponsor
- Pfizer
- Brief Summary
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against Crohn's disease or ulcerative colitis under actual status of use.
- Detailed Description
This study will be conducted with all-case investigation system in patients with Crohn's disease or ulcerative colitis.
This study will be conducted in patients who used this drug after the day of approval of dosage and administration for Crohn's disease or ulcerative colitis at contracted medical institutions. Patients who used this drug before conclusion of the contract with the medical institution will also be included in this study (retrospective patients will be included).
Therefore, Time Perspective is retrospective and prospective.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 428
- Patients with Crohn's disease or ulcerative colitis who started treatment with this drug
- Patients who received this drug for the first time at the medical institution after the day of launch of this drug.
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Infliximab [infliximab biosimilar 3] Infliximab [infliximab biosimilar 3] Patients with Crohn's Disease or Ulcerative Colitis treated by Infliximab BS
- Primary Outcome Measures
Name Time Method Number of Participants With Adverse Drug Reactions 30 weeks from the day of initial dose An adverse drug reaction (ADR) was a treatment-related adverse event, and any untoward medical occurrence attributed to Infliximab BS for I.V. Infusion 100mg \[Pfizer\] \[Infliximab Biosimilar 3\] in a participant who received this drug. Relatedness to Infliximab BS for I.V. Infusion 100mg \[Pfizer\] \[Infliximab Biosimilar 3\] was assessed by the physician.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Remission (Crohn's Disease Activity Index [CDAI]) for Crohn's Disease Baseline, Study comnletion date which is the day of visit immediately after 8 weeks have elapsed since the last dose during the observation period. Percentage of participants with remission of Crohn's disease was presented using the Crohn's Disease Activity Index score along with the two-sided 95% confidence interval (exact method).
The Crohn's Disease Activity Index score is calculated from the following 8 items: (1) the number of watery or mushy stools, (2) abdominal pain (0 to 3), (3) general condition (0 to 4), (4) symptoms and signs considered to be related to Crohn's disease (0 to6), (5) use of Lomotil/Opiate for diarrhea (0 to 1), (6) abdominal mass (0 to 5), (7) hematocrit(%), and (8) score derived from body weight, that is the sum of 2x(1)+5x(2)+7x(3)+20x(4)+30x(5)+10x(6)+6x(7)+(8). A Crohn's Disease Activity IndexI score of \<150 was considered remission.Percentage of Participants With Improvement the Crohn's Disease Activity Index for Crohn's Disease Study comnletion date which is the day of visit immediately after 8 weeks have elapsed since the last dose during the observation period. Percentage of participants with improvement of Crohn's disease was presented using the Crohn's Disease Activity Index score along with the two-sided 95% confidence interval (exact method).
The Crohn's Disease Activity Index score is calculated from the following 8 items:(1) the number of watery or mushy stools, (2) abdominal pain (0 to 3), (3) general condition (0 to 4), (4) symptoms and signs considered to be related to Crohn's disease (0 to6), (5) use of Lomotil/Opiate for diarrhea (0 to 1), (6) abdominal mass (0 to 5), (7) hematocrit(%), and (8) score derived from body weight, that is the sum of 2x(1)+5x(2)+7x(3)+20x(4)+30x(5)+10x(6)+6x(7)+(8). The Crohn's Disease Activity Index improvement was defined as a decrease of 25% or more and 70 points or more in Crohn's Disease Activity Index score after treatment with Infliximab BS for I.V. Infusion 100mg \[Pfizer\] \[Infliximab Biosimilar 3\] compared with the Crohn's Disease Activity Index score before treatment.Percentage of Participants With Remission (Partial Mayo) Score for Ulcerative Colitis Baseline, Study comnletion date which is the day of visit immediately after 8 weeks have elapsed since the last dose during the observation period. Percentage of participants with remission of Ulcerative colitis was presented using the partial Mayo score along with the two-sided 95% confidence interval (exact method).
The partial Mayo score is the sum of the subscores for the following 3 domains with a range of 0 to 9 points; the number of bowel movements subscore (0 to 3), rectal bleeding subscore (0 to 3), and physician's global assessment subscore (0 to 3). Partial Mayo score of \<2 was considered partial Mayo score remission.Percentage of Participants With Improvement (Partial Mayo) Score for Ulcerative Colitis Study comnletion date which is the day of visit immediately after 8 weeks have elapsed since the last dose during the observation period. Percentage of participants with improvement of Ulcerative colitis was presented using the partial Mayo score along with the two-sided 95% confidence interval (exact method).
The partial Mayo score is the sum of the subscores for the following 3 domains with a range of 0 to 9 points; the number of bowel movements subscore (0 to 3), rectal bleeding subscore (0 to 3), and physician's global assessment subscore (0 to 3). Partial Mayo score improvement was defined as 2 points or more reduction from baseline.Change of Mayo Score From Baseline to Study Completion Date for Ulcerative Colitis Baseline, Study comnletion date which is the day of visit immediately after 8 weeks have elapsed since the last dose during the observation period. Summary statistics of the Mayo score at baseline, at study completion date, and the change in Mayo score from baseline to study completion date in participants with Ulcerative colitis.
The Mayo score consists of 4 domains, each scored as a 0- to 3-point subscore, with higher scores indicating more severe disease activity. The 4 domains are the number of bowel movements subscore (0 to 3), rectal bleeding subscore (0 to 3), endoscopic finding subscore (0 to 3), and physician's global assessment subscore (0 to 3). The method of calculating the Mayo score is the sum of all subscores in the 4 domains, with a range of 0 to 12 points.
Trial Locations
- Locations (1)
Pfizer Local Country Office
🇯🇵Tokyo, Japan